PLAY PODCASTS
FDA reviews first-ever OTC birth control application
Episode 301

FDA reviews first-ever OTC birth control application

The Food and Drug Administration is reviewing a first-of-its-kind application from HRA Pharma for Opill. If green-lit by the agency, Opill would become the first daily, hormonal birth control pill sold without a prescription. The submission of the application follows more than six years of studies the company has run. Alice Miranda Ollstein reports.

POLITICO's Pulse Check

July 14, 20229m 38s

Audio is streamed directly from the publisher (traffic.megaphone.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

The Food and Drug Administration is reviewing a first-of-its-kind application from HRA Pharma for Opill. If green-lit by the agency, Opill would become the first daily, hormonal birth control pill sold without a prescription. The submission of the application follows more than six years of studies the company has run. Alice Miranda Ollstein reports.

Learn more about your ad choices. Visit megaphone.fm/adchoices